文献速递神经肿瘤

儿童低级别胶质瘤患者接受质子放疗较光子放疗假性进展风险增加

Increased risk of pseudoprogression among pediatric low-grade glioma patients treated with proton versus photon radiotherapy.
PubMed 文献 · Neuro Oncol · 2019-01-01

该研究分析了1998至2017年间2家机构83例接受放疗的儿童低级别胶质瘤患者的连续MRI,比较光子调强放疗(IMRT)与质子束治疗(PBT)后假性进展(PsP)的发生率。结果显示PBT组PsP发生率45%(23/51)高于IMRT组25%(8/32),PBT与放疗后病灶增大风险升高相关(HR 2.15,95%CI 1.06-4.38,P=0.048),放疗剂量>50.4 Gy(RBE)同样预测PsP发生率更高(HR 2.61,95%CI 1.20-5.68,P=0.016)。

要点

  • 儿童低级别胶质瘤放疗后假性进展总体发生率为37%(31/83)。
  • 质子束治疗组假性进展发生率45%(23/51)高于调强放疗组25%(8/32)。
  • 放疗剂量>50.4 Gy(RBE)与假性进展风险升高相关(HR 2.61)。

核心结论

  • 儿童低级别胶质瘤患者放疗后假性进展发生率较高,尤其是接受质子束治疗者。
  • 在放疗后第一年内评估低级别胶质瘤对放疗的反应时应考虑假性进展。

研究设计与样本

  • 回顾性分析1998至2017年间2家机构83例接受放疗的儿童低级别胶质瘤患者的连续MRI扫描。
  • 假性进展定义为进行性病灶随后未经治疗缩小或稳定至少一年。

主要发现

  • 32例(39%)接受调强放疗,51例(61%)接受质子束治疗;队列中位放疗剂量为50.4 Gy(RBE)(范围45-59.4 Gy[RBE])。
  • 31例(37%)出现假性进展,其中调强放疗组8/32(25%),质子束治疗组23/51(45%)。
  • 质子束治疗患者放疗后病灶增大风险显著更高(HR 2.15,95%CI 1.06-4.38,P=0.048)。
  • 放疗剂量>50.4 Gy(RBE)同样预测假性进展发生率更高(HR 2.61,95%CI 1.20-5.68,P=0.016)。
  • 多变量分析证实放疗方式(P=0.03)和放疗剂量(P=0.01)对假性进展发生率的独立影响。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pseudoprogression (PsP) is a recognized phenomenon after radiotherapy (RT) for high-grade glioma but is poorly characterized for low-grade glioma (LGG). We sought to characterize PsP for pediatric LGG patients treated with RT, with particular focus on the role of RT modality using photon-based intensity-modulated RT (IMRT) or proton beam therapy (PBT). METHODS: Serial MRI scans from 83 pediatric LGG patients managed at 2 institutions between 1998 and 2017 were evaluated. PsP was scored when a progressive lesion subsequently decreased or stabilized for at least a year without therapy. RESULTS: Thirty-two patients (39%) were treated with IMRT, and 51 (61%) were treated with PBT. Median RT dose for the cohort was 50.4 Gy(RBE) (range, 45-59.4 Gy[RBE]). PsP was identified in 31 patients (37%), including 8/32 IMRT patients (25%) and 23/51 PBT patients (45%). PBT patients were significantly more likely to have post-RT enlargement (hazard ratio [HR] 2.15, 95% CI: 1.06-4.38, P = 0.048). RT dose >50.4 Gy(RBE) similarly predicted higher rates of PsP (HR 2.61, 95% CI: 1.20-5.68, P = 0.016). Multivariable analysis confirmed the independent effects of RT modality (P = 0.03) and RT dose (P = 0.01) on PsP incidence. Local progression occurred in 10 patients: 7 IMRT patients (22%) and 3 PBT patients (6%), with a trend toward improved local control for PBT patients (HR 0.34, 95% CI: 0.10-1.18, P = 0.099). CONCLUSIONS: These data highlight substantial rates of PsP among pediatric LGG patients, particularly those treated with PBT. PsP should be considered when assessing response to RT in LGG patients within the first year after RT.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Ludmir EB, Mahajan A, Paulino AC, et al. Increased risk of pseudoprogression among pediatric low-grade glioma patients treated with proton versus photon radiotherapy. Neuro Oncol. 2019. PMID: 30753704. doi:10.1093/neuonc/noz042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。